All Updates

All Updates

icon
Filter
Partnerships
GenKOre partners with Revvity to develop gene therapy treatments
Human Gene Editing
Jun 18, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Human Gene Editing

Human Gene Editing

Jun 18, 2024

GenKOre partners with Revvity to develop gene therapy treatments

Partnerships

  • CRISPR-based gene-editing company GenKOre has partnered with diagnostic and life sciences company Revvity's Gene Delivery franchise to develop gene therapy treatments for ocular disorders such as Leber congenital amaurosis 10 (LCA10) and Usher syndrome type 2A (USH2A).

  • Under the collaboration, GenKOre will use its proprietary TaRGET (tiny nuclease, augment RNA-based genome-editing technology) gene-editing platform combined with Revvity's adeno-associated virus (AAV) vector development technology to develop in vivo gene-editing therapies. The collaboration also aims to validate TaRGET's applicability for in vivo therapy, expand its utility for rare diseases, and address unmet medical needs through genomic medicine. 

  • GenKOre is a biotechnology company based in South Korea that specializes in gene-editing therapies. Its core technology, the TaRGET platform, includes various tools such as TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI for gene activation and inhibition, and TaRGET-FREE for gene knock-in applications. This platform consists of hypercompact CRISPR-Cas tools, which can be delivered via a single AAV vector, unlike the CRISPR-Cas9 system.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.